CoChat

Adoption of Telemedicine for Type 1 Diabetes Care During the COVID-19 Pandemic

Open access
Lee, Joyce M., Carlson, Emily, Albanese-O'Neill, Anastasia, Demeterco-Berggren, Carla, Corathers, Sarah D., Vendrame, Francesco, Weinstock, Ruth S., Prahalad, Priya, Alonso, Guy Todd, Kamboj, Manmohan, DeSalvo, Daniel J., Malik, Faisal S., Izquierdo, Roberto, Ebekozien, Osagie · 2021 · Diabetes Technology & Therapeutics
Cited by 77

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background: We describe the utilization of telemedicine visits (video or telephone) across the type 1 diabetes (T1D) Exchange Quality Improvement Collaborative (T1DX-QI) during the COVID-19 pandemic. Metrics, site-level survey results, and examples of interventions conducted to support telemedicine in T1D are shown. Materials and Methods: Thirteen clinics (11 pediatric, 2 adult) provided monthly telemedicine metrics between December 2019 and August 2020 and 21 clinics completed a survey about their telemedicine practices. Results: The proportion of telemedicine visits in T1DX-QI before the pandemic was <1%, rising to an average of 95.2% in April 2020 (range 52.3%–99.5%). Three sites initially used mostly telephone visits before converting to video visits. By August 2020, the proportion of telemedicine visits decreased to an average of 45% across T1DX-QI (range 10%–86.6%). The majority of clinics (62%) performed both video and telephone visits; Zoom was the most popular video platform used. Over 95% of clinics reported using CareLink™, Clarity ® , Glooko™, and/or t:connect ® to view device data, with only one center reporting automated data upload into the electronic medical record. The majority of centers had multidisciplinary teams participating in the video visits. All sites reported reimbursement for video visits, and 95% of sites reported coverage for telephone visits early on in the pandemic. Conclusions: There was rapid adoption of telemedicine in T1DX-QI during the COVID-19 pandemic. Future insurance reimbursement for telemedicine visits and the ideal ratio of telemedicine to in-person visits in T1D care remain to be determined.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2021.0080

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 77

Metadata

Authors
Lee, J. M., Carlson, E., Albanese-O'Neill, A., Demeterco-Berggren, C., Corathers, S. D., Vendrame, F., Weinstock, R. S., Prahalad, P., Alonso, G. T., Kamboj, M., DeSalvo, D. J., Malik, F. S., Izquierdo, R., & Ebekozien, O.
Venue
Diabetes Technology & Therapeutics
Published
2021-09-01
Volume
23
Issue
9
Pages
642-651
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W3155237711
Cited by
77
References
7
FWCI
13.28
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adoption of Telemedicine for Type 1 Diabetes Care During the COVID-19 Pandemic. https://app.cochat.ai/papers/10.1089/dia.2021.0080
The paper
Lee, J. M., Carlson, E., Albanese-O'Neill, A., Demeterco-Berggren, C., Corathers, S. D., Vendrame, F., Weinstock, R. S., Prahalad, P., Alonso, G. T., Kamboj, M., DeSalvo, D. J., Malik, F. S., Izquierdo, R., & Ebekozien, O. (2021). Adoption of Telemedicine for Type 1 Diabetes Care During the COVID-19 Pandemic. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2021.0080

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.